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Abstract
The human immunodeficiency virus type 1 (HIV-1) gp120 V3 loop plays a predominant role in chemokine receptor usage; however,
other linear and nonlinear gp120 domains are involved in this step of the HIV-1 replication cycle. At present, the functional relationship
between V3 and these domains with regard to coreceptor usage is unclear. To gain insights into the nature of this relationship in naturally
selected viral variants, we developed a recombinant strategy based on two different gp120 backbones derived from CXCR4 (X4)- and CCR5
(R5)-tropic viral strains, respectively. Using this recombinant model system, we evaluated the phenotype patterns conferred to chimeric
viruses by exogenous V3 loops from reference molecular clones and samples from infected subjects. In 13 of 17 recombinants (76%), a
comparable phenotype was observed independently of the gp120 backbone, whereas in a minority of the recombinant viruses (4/17, 24%)
viral infectivity depended on the gp120 context. No case of differential tropism using identical V3 sequence in the two gp120 contexts was
observed. Site-directed mutagenesis experiments were performed to evaluate the phenotypic impact of specific V3 motifs. The data indicate
that while the interaction of HIV-1 with chemokine receptors is driven by V3 loop and influenced by its evolutionary potential, the gp120
context plays a role in influencing the replication competence of the variants, suggesting that compensatory mutations occurring at sites other
than V3 are necessary in some cases.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Human immunodeficiency virus type 1 (HIV-1) entry
into target cells is currently explained from a molecular
perspective. Conformational changes occurring in the enve-
lope glycoprotein gp120 after binding to CD4 cause the
exposure of a binding site for chemokine receptors (HIV-1
coreceptors) (Rizzuto and Sodroski, 2000; Rizzuto et al.,
1998; Wu et al., 1996; Wyatt and Sodroski, 1998; Zhang et
al., 1999). Although several chemokine receptors are used
by HIV-1 as coreceptors for entry in vitro (Hill et al., 1997;
Berger, 1997; Berger et al., 1999), CCR5 and CXCR4
molecules seem to play a major role in vivo. Typically, the
virus involved in primary infection uses only CCR5 as
coreceptor (Berger et al., 1999); CXCR4 is involved later in
the infection, albeit not invariably (Connor et al., 1997).
Modifications in coreceptor usage and the consequent tran-
sition in cellular tropism are critical features of the viral
pathogenic potential of HIV-1 and affect disease progres-
sion (Connor et al., 1997).
A large body of studies has recently addressed the HIV-1
determinants of chemokine receptor usage at the molecular
level. On the one hand, it has been documented that the
gp120 V3 domain influences viral tropism (Este et al., 1999;
Fouchier et al., 1995; Hoffman and Doms, 1999; Hung et
al., 1999; Kato et al., 1999; Ross and Cullen, 1998; Wang et
al., 1998, 1999) and that an exchange of V3 sequences
between CCR5-tropic (R5) and CXCR4-tropic (X4) strains
is paralleled by a switch in the tropism of the resulting
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chimeric viruses (Cocchi et al., 1996). On the other hand,
mutational analysis has demonstrated that some highly con-
served, nonlinear residues in a region that connects the
bridging sheet and the outer domain of gp120 play a central
role in CCR5 coreceptor usage (Rizzuto and Sodroski,
2000; Rizzuto et al., 1998). Although these data appear to be
conflicting, it has been observed that the base of the V3 loop
is very close to the bridging sheet (Wang et al., 1999),
suggesting that the two structures are functionally related
domains with regard to coreceptor utilization. In addition, it
has been observed that gp120 domains other than V3,
namely the V4–V5 and C4 regions, may influence this early
step of the virus life cycle (Carillo and Ratner, 1996; Hu et
al., 2000; Smyth et al., 1998) and that glycosylation sites
near the V1/V2 and V3 loops may play a critical role in
maintaining proper loop conformation for optimal interac-
tion with the receptors (Ogert et al., 2001).
The interaction between HIV-1 and chemokine receptors
has been seen to be susceptible to pharmacologic interven-
tion (Sodroski, 1999). Indeed, the HIV-1 env gene under-
goes extensive intrahost evolution during the infection
(Bagnarelli et al., 1999; Menzo et al., 1998; Salvatori et al.,
1997; Scarlatti et al., 1997; Shankarappa et al., 1998; Shan-
karappa et al., 1999; Wolinski et al., 1996). Although sev-
eral classes of promising compounds have been identified
that efficiently block coreceptors, the design of new inhib-
itors requires that the effects of HIV-1 evolution under
selective pressure are considered. During the infection,
gp120 is exposed to selective forces of different nature,
including positive selection exerted by the host’s immune
response and functional (negative) selection for amino acid
changes in domains that interact with cellular structures
(Yamaguchi-Kabata and Gojobori, 2000). Theoretical con-
siderations have suggested that the sites for receptor binding
are relatively conserved in gp120 because of their functional
role, while antigenic domains are more variable, because
variants with mutations at these sites enable the virus to
escape recognition by the host’s immune system. Recent
data (Wang et al., 1999; Hung et al., 1999) have suggested,
however, that this assumption does not exactly reflect the
biological impact of interactions between different amino
acid substitutions.
To gain greater insights into the nature of the relationship
between V3 and the gp120 context with regard to coreceptor
usage, a recombinant strategy was optimized to obtain V3
chimeric viruses starting from two HIV-1 gp120 backbones,
X4-tropic and R5-tropic-derived, respectively. Using this
approach, the tropism and replication dynamics of the re-
combinant viruses were assayed and evaluated compara-
tively, and a sequence-function analysis of V3 loops from
sequential samples (replicating plasma virus) of six infected
subjects was performed. Site-directed mutagenesis experi-
ments were also carried out to address the phenotypic role
of specific motifs characterizing the V3 sequences under
study.
Results
Development of molecular vectors
Two molecular vectors were developed in the present
study (Fig. 1). First, the pNL4-3 molecular clone was mod-
ified to reduce the human DNA regions flanking the HIV-1
DNA and to obtain a single StuI restriction site. Further-
more, the original pUC vector was substituted with the
pCR-Script vector; the modified plasmid was designated
pNLmod. The X4-derived, HIV-1 molecular vector (desig-
nated pNLmodV3) was obtained starting from pNLmod.
As shown in Fig. 1A, a portion of the env gene spanning a
region from StuI to NheI restriction sites was modified by
PCR-directed mutagenesis to obtain a shorter fragment
where the V3-coding sequence was deleted and generate a
new restriction site (NruI) where exogenous V3 sequences
could be inserted. The deletion and the new restriction site
were obtained using the StuI sense primer and the NheI–
NruI antisense, deletion-bearing primer encompassing the
162 nt of the V3 region. The mutagenized fragment (271 bp)
was verified by sequence analysis, digested using the re-
striction enzymes, and ligated in the pNLmod, thus obtain-
ing the final form designated pNLmodV3. Competent cells
were transformed, plasmids were purified from single col-
onies and checked for the proper substitution of the V3
insert by digestion with NheI, StuI, and NruI and sequenc-
ing. The R5-derived HIV-1 molecular vector, designated
pNLmod(AD8gp120)V3, was obtained starting from the
NL4-3(AD8), which contains the KpnI–BsaMI AD8gp120
(Freed and Martin, 1994) and pNLmod. Briefly, the region
encompassing the AD8gp120 in the NL4-3(AD8) was am-
plified using primers that included the restriction sites
EcoRI and HpaI. The pNLmod and the amplified fragment
(2939 bp) were digested with the two enzymes and ligated
at a molar ratio of 1/3. Plasmid was purified using standard
procedures and a number of clones were checked by diges-
tion with EcoRI, HpaI, and NheI (missing in AD8gp120)
and sequenced for the correct substitution of the original
gp120 with the AD8gp120. As shown in Fig. 1B, the frag-
ment of pNLmod(AD8gp120), spanning a region from StuI
to BsaBI restriction sites, was modified by PCR-directed
mutagenesis to obtain a shorter fragment in which the V3
sequence was deleted. As for the pNLmodV3, the frag-
ment was modified to introduce the NruI restriction site. The
mutagenized fragment (588 bp) was verified by sequence
analysis, digested using the StuI and BsaBI restriction en-
zymes, and ligated in the pNLmod(AD8gp120), thus obtain-
ing the final form designated pNLmod(AD8gp120)V3.
Validation of the recombinant analysis
The recombinant method was validated using V3 se-
quences from molecular clones NL4-3 (X4 phenotype),
AD8 (R5 phenotype), and SF2 (dual-tropic virus). As
shown in Table 1, all the recombinant viruses obtained
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Fig. 1. Generation of the V3 vectors. (A) pNLmodV3. The sequence of NL4-3 env gene (from the StuI to the NheI restriction sites) was modified by
PCR-directed mutagenesis to obtain the V3-gp120 fragment. The fragment containing a new restriction site (NruI) was reinserted into pNL4-3. (B)
pNLmod(AD8gp120)V3. The fragment of pNLmod(AD8gp120), spanning a region from restriction sites StuI to BsaBI, was modified by PCR-directed
mutagenesis to obtain the NruI restriction site containing V3 fragment (see Materials and methods for details). The mutagenized V3 fragment was
reinserted into the pNLmod(AD8-gp120). The deletion-bearing primers are indicated as an interrupted arrow encompassing the V3 sequence in A and B. In
both vectors, the unique NruI site is used for cloning the V3 loop. Open boxes, NL4-3 backbone; gray boxes, AD8 backbone; barred boxes, deleted V3
sequence.
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using the NL4-3-derived backbone and two of the three
obtained using the AD8-derived backbone maintained the
same coreceptor usage as the donor viruses. The SI/NSI
phenotype was also maintained, as demonstrated by the
MT2 assay. All the recombinant viruses were able to rep-
licate in PBMCs from two different donors, with the sole
exception of the viral recombinant obtained by cloning the
NL4-3 V3 sequence into AD8gp120 (nonfunctional virus;
see below).
Recombinant phenotypes conferred by V3 viral variants
from sequential samples of HIV-1-infected patients
The clonal HIV-1 V3 sequences from six untreated sub-
jects were obtained from three sequential samples spanning
a period of 2 years by amplification, cloning, and sequenc-
ing (Bagnarelli et al., 1999). After sequence analysis, those
considered representative (i.e., dominant in each sample)
and those showing motifs of particular interest were se-
lected for cloning into the NruI site of the vectors (Table 2).
In the context of the NLgp120 background (X4), the
majority of recombinant viruses exhibited an R5 phenotype
(Table 3A). Fourteen of the 20 recombinant viruses from the
six subjects were able to replicate on U87-CCR5 cells, and
one (E1) tested dual-tropic. As shown in Table 3A, all but
two R5 viruses were able to replicate both in PM1 cells and
in PBMCs from uninfected donors and, as expected, none
replicated on MT2 cells. The dual-tropic E1 virus was
unable to replicate in either PM1 or MT2 cells, even when
the inoculum was raised to 100 ng of p24Aggag/106 cells/ml.
Similarly, the C5 recombinant was unable to infect PM1
cells at 40 ng of p24Aggag. In five cases, the phenotype of
the recombinant viruses was undefined (nonfunctional vi-
ruses). Interestingly, in the clones from subject B, the evo-
lution of the V3 loop was paralleled by the loss of the R5
phenotype. Growth on cells expressing CCR2b, CCR3,
BOB, and BONZO coreceptors was invariably negative for
these recombinant viruses (data not shown).
Seventeen of the 20 V3 loops were also evaluated in the
context of an R5 gp120 background (AD8gp120). Eleven of
the 17 recombinant viruses (Table 3B) showed an R5 phe-
notype, 1 was dual-tropic (AD8-B4 clone), and in 5 cases
the recombinant virus was not functional. All R5 viruses
except the E3 viral chimera were able to grow in PBMCs
and PM1. The B4 recombinant virus was able to replicate
only in CCR5- and CXCR4-expressing U87 cells.
On the whole, 10 V3 sequences conferred an R5 pheno-
type to the recombinant viruses, and 3 sequences were
unable to produce an infectious chimera independently of
the gp120 context. Differences were observed in some cases
using the two gp120 backbones. In the AD8gp120 context,
sequences A3 and B4 produced an R5 and a dual-tropic
R5/X4 virus, respectively, but these V3 loops were unable
to produce an infectious virus when inserted in the context
of NLgp120. By contrast, the E5 sequence conferred an R5
phenotype to the recombinant virus only in the context of
NLgp120. Similarly, the dual-tropism of the E1 recombi-
nant virus was dependent on the NLgp120 context, since
this phenotype was not confirmed in AD8gp120.
Finally, the replication dynamics of the R5 viruses was
similar independently of the gp120 background (Fig. 2), the
levels of virus released in the supernatant on day 9 postin-
fection being comparable in most cases (Mann-Whitney P
 NS). Nevertheless, in two cases (A2 and E3 V3 se-
quences) the replication dynamics benefited more from the
AD8gp120 context, as the amount of p24Aggag released on
day 9 postinfection in U87-CCR5 cells by the two AD8
recombinant viruses was about 2 log higher than that ob-
served using the equivalent NL recombinant viruses.
Site-directed mutagenesis of specific V3 motifs and viral
phenotype
Site-directed mutagenesis experiments were performed
to evaluate the role of specific V3 motifs observed in the
sequences under study.
Table 1
Phenotypic analysis of recombinant control strains
V3 sequence
(donor phenotype)a
Growth of recombinant virus in cell cultureb Phenotype of
recombinant virus in
the NLgp 120 contextPHA-PBMCs MT2 PM1 U87-CCR5 U87-CXCR4
NL4-3 (X4)      X4
AD8 (R5)      R5
SF2 (R5/X4)      R5/X4
V3 sequence
(donor phenotype)a
Growth of recombinant virus in cell cultureb Phenotype of
recombinant virus in
the AD8gp 120 contextPHA-PBMCs MT2 PM1 U87-CCR5 U87-CXCR4
NL4-3 (X4)      Undefinedc
AD8 (R5)      R5
SF2 (R5/X4)      R5/X4
a Reference strain from which the V3 sequence was derived.
b Replication of recombinant viruses is assessed by p24 antigen production; values indicative of infection are over 0.200 ng/ml.
c Undefined phenotype: the recombinant is unable to replicate in any of the cell lines tested (non functional virus).
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First, the importance of the QR insertion and the 126
deletion in the V3 sequence of NL4-3 was investigated. The
results indicate that the QR insertion is crucial for the X4
phenotype of NL4-3. Its deletion determines a nonfunc-
tional virus in the NL4-3 gp120 and does not modify the
features of the NL4-3 V3 inserted in the AD8gp120 (Table
4). On the other hand, the insertion of the QR motif in AD8
and E3 V3 sequences impairs the usage of R5 coreceptors
(not shown). These results, indicating that the QR motif is
uniquely functional in the NL4-3 gp120 context, strongly
suggest that compensatory modifications are present in the
NLgp120, allowing CXCR4 coreceptor usage by this pecu-
liar V3 loop. Furthermore, the insertion of an isoleucine at
position 26 (missing in the NL V3) does not confer repli-
cation competence to the NLQR chimeras, independently
of the gp120 context.
Second, the peculiarities of the SF2 and AD8 V3 se-
quences were evaluated. The SF2 V3 sequence differs from
the B consensus (theoretically, an R5 phenotype) in 4 amino
acidic residues. One of these, an arginine (R) at position 25,
is considered a major determinant for the X4 phenotype (de
Jong et al., 1992). Mutation R25D caused the loss of X4
tropism in the SF2-D25 chimera, but the inverse mutation
(D25R) was insufficient to change the original phenotype in
the AD8-R25 recombinant. This means that the presence of
a basic residue at position 25 is not per se associated with an
X4 phenotype. Because another difference between SF2 and
AD8 V3 loops is the lysine (K) at position 32, the impor-
tance of this residue was evaluated not only in the SF2 and
AD8 V3 sequences, but also in V3 clones from some sub-
jects (E3, E4, E5, B4, and B5). The results (clones from
subjects B and E not shown in Table 3) indicate that the
residue at position 32 can be either a glutamine (Q) or a
lysine (K) with no phenotypic change.
Third, the characteristics of the five nonfunctional re-
combinant chimeras obtained in the NL backbone and the
role of specific mutations on growth characteristics were
evaluated. The nonfunctional recombinants were unable to
grow in any of the coreceptor-expressing cells used in this
study, although the V3 sequences were obtained from ac-
tively replicating viruses in vivo. These in vitro results
could be explained either with the use of a different, pres-
ently unknown coreceptor or, more probably, with the lack
of compensatory modifications in the gp120 backbone re-
quired for correct coreceptor usage. The latter condition
probably occurred in the B4 V3 sequence, which was non-
Table 2
Amino acid alignments of the V3 loop in control strains and clones from patients










1 10 20 30 35
B-clade consensusc NCTRPNNNTRKSIHI..GPGRAFYTTGE..IIGDIRQAHCN 35 100 3
AD8 –––––––––––––––..––––––––––D..––––––––––– 35 97 3 AF004394
SF2 –––––––––––––Y–..––––––H–––R..––––––K–––– 35 89 6 K02007
NL4–3 –––––––––––––R–QR––––––V–I–K...––NM–––––– 36 72 8 U26942
A2 (RNA1, 23%) –––––––––––G–––..–––––I––––D..––––––––Q–– 35 89 3 AF105726
A3 (RNA2, 33%) ––––––––––RG–––..–––G–I––R–D..––––––––Y–T 35 80 3 AF105732
A4 (RNA3, 60%) ––––––––––RG–––..––––––––––D..––––––K–Y–T 35 86 4 AF105745
A5 (RNA3, 7%) D–R–––––––RG––V..–––K–I––––D..––––––––Y–T 35 77 4 AF105747
B1 (RNA1, 53%) –––––––––––G–––..–––––––A––D..––––––––––– 35 94 3 AF105760
B6 (RNA1, 13%; RNA2, 27%) –––––––––––G–––..–––S––––––D..––––––––––– 35 94 2 AF105761
B3 (RNA2, 7%) –––––––––––G–R–..–––––V–AAEK..––––––––––– 35 80 5 AF105785
B4 (RNA2, 7%; RNA3, 20%) –––––––––K–G–R–..––––TV–AAEK..––––––––––– 35 74 5 AF105776
B5 (RNA3, 47%) –––––––––K–G–R–..––––KV–AAEK..––––––––––– 35 74 6 AF105791
C2 (RNA1, 25%) ––I––––––––––S–..–––––––––––..–––N––––––– 35 91 4 AF105806
C4 (RNA2, 20%) –––––––––––––N–..––––––––––D..––––––––––– 35 94 3 AF105822
C5 (RNA3, 40%) –––––G–––––––N–..––––––––––D..–T––––––––– 35 89 3 AF105837
D1 (RNA1, 54%; RNA3, 27%) –––––––––––––––..–Q–––––A–––..––––––––––– 35 94 3 AF105847
D2 (RNA2, 65%; RNA3, 27%) –––––––––––––P–..–––––––––––..––––––––––– 35 97 3 AF105859
E1 (RNA1, 40%) –––––––––––––––..–L–––––A––ATR––––––––––– 37 87 5 AF105891
E3 (RNA1, 7%) –––––S––A––G–––..–––––––––––..–T––––––––– 35 87 3 AF105900
E4 (RNA2, 57%; RNA3, 46%) –––––––––––––––..–––––––A–ETTR––––––––––– 37 84 4 AF105903
E5 (RNA3, 23%) –––––––––––––––..Q––––––A––ATR––––––––––– 37 84 5 AF105922
F1 (RNA1, 73%; RNA3, 36%) –––––––––––G–––..–––––––A––D..––––––––––– 35 91 3 AF105929
F2 (RNA2, 63%) –––––––––––G–––..–––––––A––N..––––––––––– 35 91 4 AF105940
a Recombinant viruses are identified by the patient and a number referring to the V3 sequence (shown in the second column) inserted in each of the V3
vectors. The clinical sample and the serial time points from which the sequence was derived along with its frequence in the sample are reported in parentheses.
b The sequences are aligned with the B-clade consensus sequence; dashes indicate identity with the B consensus and dots represent gaps introduced to
maintain the alignment.
c The B-clade consensus sequence shows the most common amino acid found in each position among 1912 viral variants (Human Retroviruses and AIDS
1999, Theoretical Biology and Biophysics Group T-10, Los Alamos National Laboratory, Los Alamos, NM).
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functional using the NLgp120 vector, but tested dual-tropic
in the AD8gp120 context (see above). Moreover, as shown
in Fig. 3, the presence of a phenylalanine (F) at position 20
enhanced the growth of the A2-20F and A5-20F mutants on
U87-CCR5 cells. In clone B4, the same mutation is crucial
in R5-expressing cells and, in this context, the V to F
mutation induces the appearance of an X4/R5 dual-tropic
virus. Notably, this recombinant virus showed an SI phe-
notype, as demonstrated by the MT2 assay (not shown).
Whereas an X4 tropism might have been expected in this
case owing to the high net charge of this sequence, the
acquisition of an R5 phenotype was unpredictable. In fact,
the substitution of isoleucine (I) or valine (V), which have
an alchilic radical, with phenylalanine, which has an aro-
Table 3




A. Replication in cell culture of NL recombinantsa Phenotype of
recombinant
virusesPHA-PBMCs PM1 MT2 U87-CCR5 U87-CXCR4
A2      R5
A3      Undefined
A4      R5
A5      R5
B1      R5
B6      R5
B3      Undefined
B4      Undefined
B5      Undefined
C2      R5
C4      R5
C5  b    R5
D1  b    R5
D2      R5
E1  c c   R5 X4
E3      R5
E4      Undefined
E5  b    R5
F1      R5




B. Replication in cell culture of AD8 recombinantsa Phenotype of
recombinant
virusesPHA-PBMCs PM1 MT2 U87-CCR5 U87-CXCR4
A2      R5
A3      R5
A4      R5
A5      R5
B1      R5
B6      R5
B3      Undefined
B4   b   R5 X4
B5      Undefined
C2      R5
C4 NTd NT NT   R5
C5
D1
D2      R5
E1      Undefined
E3  b    R5
E4      Undefined
E5      Undefined
F1      R5
F2
a HIV-1 replication in cell cultures (on day 14 p.i., PBMCs, PM1, MT2; on day 9 p.i., U87 cells expressing the coreceptors) is expressed as follows: ,
p24Ag0.2 ng/ml;, p24Ag ranging from 0.200 to 10 ng/ml;, p24Ag ranging from 10 to 1000 ng/ml;, p24Ag1000 ng/ml. The viral inoculum
used for the infections was as described under Materials and methods, unless otherwise specified.
b Inoculum of 40 ng/ml.
c Inoculum of 100 ng.
d NT, not tested.
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matic radical, could strongly affect the tertiary structure of
the loop, giving rise to the observed phenotypes. However,
the same mutation in the context of clones B3 and B5 did
not change the original phenotype, further highlighting the
sensitivity of the V3 sequence, as these two variants differed
from clone B4 only by the residue upstream the mutated
valine (V), an alanine (A), and a lysine (K), respectively.
Finally, the substitutions of charged residues determined
phenotype modifications. In clone A3, the substitution of
the strongly basic arginine (R) 23 with a neutral threonine
Fig. 2. Influence of the gp120 backbone on coreceptor usage of recombinant viruses. On the left, clone designations and V3 loops inserted into the vectors,
aligned with the B-clade consensus. After infection the levels of p24Aggag in U87 cells expressing the specified coreceptor on day 9 postinfection are reported
in the graphs on the right. Black boxes, V3 recombinant in NLgp120; gray boxes, V3 recombinant in AD8gp120. Asterisks close to the B4 columns indicate
that the p24Aggag values for the dual-tropic B4 in backbone AD8 were observed on day 17 postinfection as this virus showed a late phenotype on both U87
cell lines.
Table 4
Effect of amino acid substitutions on V3 residues of reference strains




1 10 20 30 35
B-clade consensus NCTRPNNNTRKSIHI..GPGRAFYTTGEIIGDIRQAHCN
NL4-3 –––––––––––––R–QR––––––V–I–K.––NM–––––– X4 Undefined
NLQR –––––––––––––R–..––––––V–I–K.––NM–––––– Undefined Undefined
NLQR-126 –––––––––––––R–..––––––V–I–KI––NM–––––– Undefined Undefined
AD8 –––––––––––––––..––––––––––D––––––––––– R5 R5
AD8-QR –––––––––––––––QR––––––––––D––––––––––– Undefined NT
AD8-R25 –––––––––––––––..––––––––––R––––––––––– R5 NT
AD8-K32 –––––––––––––––..––––––––––D––––––K–––– R5 NT
SF2 –––––––––––––Y–..––––––H–––R––––––K–––– R5/X4 R5/X4
SF2-D25 –––––––––––––Y–..––––––H–––D––––––K–––– R5 NT
SF2-Q32 –––––––––––––Y–..––––––H–––R––––––Q–––– R5/X4 NT
a Amino acid substitutions are specified in the clone name and underlined in the V3 sequence (second column).
b V3 loops are aligned with the B-clade consensus sequence; see legend to Table 1.
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(T) was sufficient to confer an R5 phenotype (Fig. 3). In the
context of the E4 sequence, a substitution of glutamic acid
(E) with glycine (G) at position 24 determines a clear shift
from nonfunctional, to R5-recombinant. In clone E5, the
change from a glutamine (Q) to a glycine (G) at position 15
improved replication capacity on R5-expressing cells. Com-
paring this E5 Q15G mutant with clone E1, the leucine (L)
at position 16 is responsible for the X4 phenotype of the
latter.
Discussion
The sequence-function study described here is, to our
knowledge, the first comparative analysis of the phenotype
conferred by naturally selected V3 sequences from clinical
samples using two different gp120 contexts. The genetic
divergence between the two gp120 backbones used in this
study is about 10%; the two sequences differ by 51 amino
acid residues and four insertions or deletions of one to three
residues, and these differences are equally distributed
throughout the variable and conserved gp120 regions. Using
these different backbones, we addressed the phenotype con-
ferred by exogenous V3 sequences. The data document that,
in most cases, HIV-1 coreceptor usage is driven by the V3
loop independent of the gp120 context; in a minority of the
sequences analyzed, the replication competence of the vari-
ants is influenced by the backbone. No case of differential
tropism using identical V3 sequence in the two HIV-1
gp120 was observed.
Intrahost evolution of viral populations confer specific
characteristics to HIV-1, including changes in pathogenesis
over time, escape from host immune response and antiviral
therapy, and modified tissue tropism. The viral quasispe-
cies, defined by a dominant sequence and a spectrum of
mutants, may be relatively stable for a number of generation
cycles, although variants within the quasispecies are con-
tinuously competing (Domingo and Holland, 1997; Do-
mingo, 2000). During the natural infection, the HIV-1 sur-
face proteins are exposed to positive and negative selection
for amino acid changes (Wyatt and Sodroski, 1998;
Yamaguchi-Kabata and Gojobori, 2000); although negative
selection seems to be predominant in the whole gp120, a
number of studies have reported positive selection in major
variable domains such as V3 (Bagnarelli et al., 1999; Sato et
al., 1999; Shiino et al., 2000; Yamaguchi and Gojobori,
1997). Nonetheless, it has been suggested that positive se-
lection at a single site of conserved regions of gp120 may be
underestimated by the usual sequence analyses (Yamagu-
chi-Kabata and Gojobori, 2000) and that single mutations
may be involved in nonlinear domains with functional im-
portance. In this complex scenario, sequence-function stud-
Fig. 3. Effect of amino acid changes on growth characteristics and coreceptor usage. Clone designations and V3 loops inserted into the NLmodV3 vector,
aligned with the B-clade consensus are shown on the left. Mutated residues are indicated in the clone name and underlined in the sequence. The amounts
of p24Aggag released in the culture supernatant of U87 cells expressing the indicated coreceptor on day 9 postinfection are reported in the graphs on the right.
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ies could allow a greater understanding of the biological
role of genotypic changes that are crucial for specific phe-
notypic characteristics and of the potential cooperation be-
tween different gp120 domains.
Several data obtained in this study deserve specific com-
ment. Using V3 sequences amplified from the reference
viral strains NL4-3 (X4 phenotype), AD8 (R5), and SF2
(R5/X4), all of the recombinant viruses showed the same
phenotype as the donor virus with both AD8- and NL4-3-
derived gp120. The sole exception was the chimeric virus
obtained in the AD8gp120 context by cloning the V3 se-
quence from NL4-3; this V3 sequence (36 amino acids, net
charge 8) is characterized by a unique QR insertion and by
a missing I at position 26. We addressed the role of these
motifs and observed that QR residues are required to main-
tain the X4 phenotype in the NL4-3 gp120 context (the
QR virus is nonfunctional in both R5- and X4-expressing
cells), while the introduction of QR in viruses with R5
tropism determines a loss of infectivity. Moreover, the in-
sertion of 126 in the NLQR virus was not sufficient to
compensate for the QR deletion. Of note, these results differ
from those by other authors (Hung et al., 1998), who re-
ported replication competence of QR recombinants in the
backbone of HXB2 env. The data obtained using different
backbones suggest that the QR insertion and I deletion are
compensated for by mutations present in domains other than
V3 of the NL4-3 env; nevertheless, because the QR inser-
tion is not accepted in different V3 sequences inserted in the
NL backbone, the data also indicate that these peculiarities
are perfectly suited only for the original NL V3 determining
the CXCR4 coreceptor usage by this viral clone. The fact
that, with this single exception, the original phenotype is
transferred by the V3 loops from reference viral strains to
the recombinants irrespective of the origin of the gp120
backbone highlights the dominant role of the V3 sequence
in driving HIV-1 coreceptor usage.
The phenotype conferred by clonal V3 sequences from
samples of infected subjects was evaluated in the two gp120
backbones. Concordant results were observed in the major-
ity of cases (13/17; 76%). It is worth noting that 10 of the
13 V3 loops obtained from the replicative viruses of in-
fected subjects conferred the ability to infect CCR5-ex-
pressing cells to both the R5-tropic (AD8) and the X4-tropic
gp120 (NL4-3), while in 3 cases the recombinant viruses
tested not functional, independently of the gp120 context.
This implies that structural features of the HIV-1 gp120
linked to R5-tropism are principally driven by the V3 loop
and may have practical implications, since it has recently
been suggested that the R5 tropism confers a selective
advantage in vivo (Gorry et al., 2002). Differences in the
phenotype of the recombinant viruses were observed in 4/17
cases (24%). The V3 sequence of sample A3 gave rise to a
nonfunctional virus when inserted into the NL-derived
backbone, but to an R5 phenotype when inserted into
AD8gp120. Similarly, the recombinant viruses obtained us-
ing the V3 sequence of sample B4 resulted nonfunctional or
dual-tropic when the NL4-3 gp120 or the AD8-based vector
were used, respectively. On the other hand, the phenotype of
recombinants E1 and E5 (R5/X4 and R5, respectively) ob-
served in the NL context was not confirmed in the
AD8gp120. Because both E1 and E5 V3 loop are charac-
terized by a TR insertion, these results also suggest that
compensatory mutations at sites other than V3 are required
in several cases to maintain efficient coreceptor usage. It is
important to note that these differences always concern
variations from nonfunctional to functional viruses and not
changes in coreceptor usage, thus further highlighting the
complex interplay between the V3 loop and the gp120
context. In a few cases, the type of gp120 backbone influ-
enced replication dynamics. Sequences A2 and E3 V3 con-
ferred to the recombinants an R5 phenotype independently
of the gp120 backbone, but replication was more efficient in
the AD8gp120 background (not shown).
Entry of HIV-1 into susceptible cells is a complex event
including high-affinity interaction between CD4 and gp120
and binding to coreceptor. Several factors may influence
this process, including the concentration of CCR5 and CD4
in the cell surface (Platt et al., 1998) and the cooperation of
multiple CCR5s (Kuhman et al., 2000). The dual tropism of
the E1 (NLgp120) and B4 (AD8gp120) recombinant viruses
was confined to U87 cells only; these viruses failed to
replicate in PM1, MT2, and PBMCs. Although this feature
should be assayed specifically, possible explanation is that
the CCR5 and CXCR4 coreceptors bind the E1 and B4
recombinant gp120 weakly and function as coreceptors only
at relatively high cell surface concentration, probably
present only in U87 transfected cell lines.
Site-directed mutagenesis experiments evidenced that
substitutions at specific sites or the modification of certain
V3 loop motifs may strongly alter the interaction with
coreceptors and the replication of recombinant viruses. In
particular, the substitution of charged residues caused sig-
nificant variation from nonfunctional to R5 virus, as dem-
onstrated by the R23T or E24G substitutions in clones A3
and E4, respectively. The presence of a phenylalanine (F) at
position 20 improved the replication of mutants A2-20F and
A5-20F in U87-CCR5 cells (Fig. 3) and was also crucial for
growth in CCR5-expressing cells of clone B4 (appearance
of an X4/R5 dual-tropic virus). These data are reminiscent
of the results obtained by Wang and co-workers (1999),
who used alanine-scanning mutagenesis and identified the
role of the residue at position 20 for CCR5 utilization.
However, the same mutation in the context of clones B3 and
B5 did not change the original phenotype.
The design of antiviral strategies targeting HIV-1 core-
ceptor usage should take into account the mechanisms by
which the HIV-1 env gene evolves within the host and the
phenotypic consequences of this evolution. Although the
competitive activity of receptor ligand analogs may provide
a means to limit HIV-1 infection in the short term, it also
promotes selection of viral mutants, as demonstrated by the
use of a modified RANTES (a natural ligand for CCR5),
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which selects HIV-1 mutants able to use CXCR4 as a
coreceptor in an in vivo mouse model (Mosier et al., 1999).
Avian retroviruses have shown that small changes in surface
glycoproteins alter receptor usage (Tapliz and Coffin,
1997); similarly, HIV-1 offers a detailed evidence of the
implications of shift in coreceptor usage during the infec-
tion. The complex conformation of HIV-1 gp120 can be
modified by changes in primary structure or in posttransla-
tional mechanisms, and this is consistent with the evidence
obtained in this study using naturally selected V3 sequences
that, although the HIV-1 V3 loop has a dominant role in
coreceptor usage, the replication capacity of the variants is
influenced by compensatory mutations occurring in other
env domains.
Materials and methods
Cloning of exogenous V3 sequences into V3 vectors
HIV-1 recombinant viruses were reconstituted using ex-
ogenous V3 sequences from reference viral strains and
gp120 clones obtained from sequential plasma samples of
six subjects described previously (Bagnarelli et al., 1999).
Table 2 shows the amino acidic alignments of the V3 loops
selected for the study. These sequences were obtained from
the complete C2-V5 env clones; the original plasma sample
from which the clones were obtained, the number of amino
acid residues, the similarity to B consensus, the net charge
at pH 7.0, and the GenBank accession numbers are also
reported. Among the clones available at each time point, V3
sequences were chosen on the basis of being the more
representative (as in the cases of clones from subjects C, D,
and F) or for the presence of particular motifs. Briefly, in the
case of the A3 and A4 clones from subject A, the sequences
were chosen for their relative prevalence in the sample (33
and 60%, respectively). Clones A2 and A5 were analyzed
for the presence of two rare motifs, incorporating the amino
acid glutamine (Q) at position 34 (observed in less than
0.5% of V3 sequences of the B clade) and arginine (R) at
position 2 (never observed previously). In subject B, a
major shift in the viral population was observed starting
from the second available sample. The B3 sequence (the
least represented variant in the second sample) and se-
quences B4 and B5 (the dominant species in the third
sample, 20 and 47%, respectively) were deemed of partic-
ular interest to evaluate V3 evolution in this patient. The
principal characteristic of the majority (83%) of the V3
sequences from subject E was the insertion of a threonine
(T) and an arginine (R) downstream residue 24: the se-
quences were thus selected on the basis of the presence or
absence of this motif (clones E1 and E3). Finally, the
substitution of a glutamine (Q) (sample E5) at position 15 in
a minority of variants from the third sample was evaluated,
this residue being very rare in the B clade.
The V3 sequences were amplified in a final volume of
100 l using 50 pmol of each primer (V3s, 5-TACAG
CTGAG TAACT GTAGA AAT; V3as; 5-TATTC CATTT
TGCTC TACTAA) in the presence of 1 PCR buffer
containing 4 mM MgSO4, 0.4 mM each dNTP, and 2.5 U of
PWO DNA polymerase. Blunt-end PCR products were di-
rectly added to the digested vector, pNLmodV3 or
pNLmod(AD8gp120)V3, and the ligation reaction (final
volume 10 l) was performed in the presence of 1 ligation
buffer containing NruI (10 U) to improve the yield of the
recombinant plasmid and T4 DNA ligase (1 U). An aliquot
of 2 l was used to transform JM109 high-efficiency com-
petent cells (Promega Corp., Madison, WI) through the
heat-shock method. Single colonies were isolated and
checked for the orientation of the inserted V3 by PCR using
the primer set V31 and V3as (Bagnarelli et al., 1999).
Following growth of bacteria bearing positive clones, plas-
mids obtained by miniprep purification (Promega) were
checked by HindIII digestion (five fragments expected) and
sequencing of V3 and flanking regions in both forward and
reverse direction using primers V31 and V32 (Bagnarelli et
al., 1999) using an ABI Prism 3100 genetic analyzer (Ap-
plied Biosystems, Foster City, CA).
Site-directed mutagenesis of V3 loops
Mutagenesis of specific V3 residues and amino acid
deletions or insertions in the original V3 loop was achieved
by PCR. Primers bearing the mutated codon, synthesized in
the reverse and forward orientation, were used coupled with
primer V3s or V3as, respectively, in two different amplifi-
cation reactions. After PCR amplification, the two products
were purified, and an aliquot of each was mixed and am-
plified with the external primers (V3s and V3as). The prim-
ers used for mutagenesis experiments are listed in Table 5.
The mutated V3 loops were then inserted into the
pNLmodV3 as described above. The V3-coding sequence
of mutants was confirmed by sequencing.
Cell lines
293T cells were cultured in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% fetal calf serum
(FCS) and antibiotics (100 U/ml penicillin, 100 g/ml
streptomycin, 0.25 g/ml amphotericin B). Cells were
maintained in T75 tissue culture flasks; the day before
transfection, the confluent monolayer was passaged (1:6)
using T25 flasks following trypsinization. U87 cells stably
expressing either CD4 or CD4 plus one of the following
chemokine receptors, CCR2b, CCR3, CCR5, and CXCR4
(a kind gift from D.L. Littman) (15), were maintained in
DMEM supplemented with 0.5 antibiotics, 15% FCS, 300
g/ml G418; 1 g/ml puromycin was added to the chemo-
kine-expressing cell lines. CD4 human osteosarcoma cell
lines (HOS.CD4) expressing either BOB or BONZO were
maintained in DMEM supplemented with 0.5 antibiotics,
10% FCS, 300 g/ml G418, 1 g/ml puromycin, and 100
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g/ml hygromycin. The human CD4 T-lymphocyte cell
lines MT2 and PM1 were grown in RPMI 1640 supple-
mented with 10% FCS–phyrohemagglutinin (PHA)-stimu-
lated peripheral blood mononuclear cells (PHA blasts) were
prepared as previously described (Bagnarelli et al., 1996)
from whole blood of two different HIV-1 seronegative do-
nors by Ficoll–Hypaque density gradient centrifugation. All
cultures were incubated at 37°C in 5% CO2 atmosphere.
Virus stocks
To prepare experimental V3 recombinant viruses for
infection experiments, 293T cells were transfected by the
CaPO4 coprecipitation method by using 10–15 g of re-
combinant plamids. Two days after transfection, the virus-
containing supernatant (5 ml per T25 tissue culture flask)
was harvested and sterile-filtered through 0.2-m pore size
filters. The p24gag concentration was assessed by enzyme-
linked immunosorbent assay (NEN Life Science Products,
Boston, MA) and virus stocks were aliquoted and stored at
80°C. The titer of viral stocks in the supernatant of trans-
fectants was quite variable. In the case of the NLgp120
recombinant viruses, it ranged from 16 to 800 ng/ml of
p24Aggag; low-titer viral stocks ranging from 4 ng/ml to a
maximum of 96 ng/ml were generally obtained from the
transfection of 293T cells with the AD8gp120 recombinant
plasmid. In the case of viral chimerae able to grow on U87
cells expressing CCR5 or CXCR4, high-titer viral stocks
were obtained by infection of 5  105 cells, plated 24 h
prior to infection, with 40 ng p24Aggag of virus derived
from the supernatant of 293T transfectants. Seven days after
infection, the supernatant was harvested, aliquoted, and
stored at 80°C; p24Aggag concentration was assessed and
the V3 region was checked by sequencing.
Analysis of coreceptor usage and replication dynamics of
V3 recombinant viruses
U87 cell lines expressing CD4 alone or in combination
with the above-mentioned chemokine receptors were plated
in 24-well plates (NUNC, Roskilde, Denmark) at a density
of 50,000 cells/well/ml and infected 24 h later with a con-
centration of 4ng p24Aggag of recombinant viral stocks.
Cells were washed twice with phosphate-buffered saline,
and medium was replaced 16 h after infection. Cultures
were examined daily for syncytia formation. In the absence
of cytopathic effect (CPE), day 9 cells were passaged to a
T25 flask and cultures maintained up to day 21. Aliquots of
the supernatants were removed on days 3, 6, and 9 and
production of HIV-1 p24Aggag was determined. Cultures
were considered negative when the amount of p24gag was
consistently below 0.2 ng/ml. The MT2 and PM1 cell lines
were infected as follows: 106 cells were suspended in RPMI
and added to an aliquot of either low titer (4 ng of p24Aggag)
or high-titer (40 ng of p24Aggag) recombinant viral stocks,
to reach a final volume of 1.5 ml. Adsorption was allowed
to occur for 2 h, then the cell-free virus was carefully
washed out (three times with growth medium). Viable cells
were counted in a hemocytometer after trypan blue dye
exclusion staining, resuspended in growth medium at a
concentration of 2  105 (MT2) or 1  105 (PM1) per
milliliter, and seeded (1 ml per well) in a 24-well plate
Table 5
Primers used for mutagenizing V3 sequences
V3 loop Mutated
residuea
Orientation 5–3 primer sequence
NL4-3 QR  ACAAGAAAAAGTATCCGTATCGGACCAGGGAGAGCA
 TGCTCTCCCTGGTCCGATACGGATACTTTTTCTTGT
AD8-A3-E3 Ins QR  TATACATATACAGAGGGGACCAG
 CTGGTCCCCTCTGTATATGTATA
NL4-3 Ins 126  GTGCTTGTCTCATATTTCCTATTATTTTTC
AD8 D25R  ATACAACAGGAAGAATAATAG
 CTATTATTCTTCCTGTTGTAT
SF2 R25D  ATACAACAGGAGACATAATAG
 CTATTATGTCTCCTGTTGTAT
AD8-E3-E4-E5-B4-B5 Q32K  TGCTCTACTAATGTTACAATGTGCTTTTC
SF2 K32Q  TGCTCTACTAATGTTACAATGTGCTTGTC
A2-A5 I20F  GCATTTTATACAACAGGAGACATAA
 TTATGTCTCCTGTTGTATAAAATGC
A3. R23T  ATACAACAGGAGACATAATAG
 CTATTATGTCTCCTGTTGTAT
B3-B4-B5 V20F  ATTTTATGCAGCAGAAAAAATAATA
 TATTATTTTTTCTGCTGCATAAAAT
E4 E24G  ATGCAACAGGAACAACAAGAAT
 ATTCTTGTTGTTCCTGTTGCAT
E5 Q15G  ATACATATAGGACCAGGCAGA
 TCTGCCTGGTCCTATATGTAT
a Deletions, insertions, and codon substitutions are indicated along with the clone identification. Mutations in the sequence are underlined and in bold.
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(Nunc), in duplicate. Day 4, day 7, and day 14 supernatant
aliquots were removed for secreted p24Aggag measure-
ments. Subcultures were performed on days 4, 7, and 11.
Cultures were maintained up to day 14 and checked daily
for syncytia formation. PHA-stimulated peripheral blood
mononuclear cells (PBMCs) from uninfected donors were
washed and resuspended in complete medium; the concen-
tration was adjusted to 1  106 cells ml, and then 0.5 ml of
recombinant viral stocks containing 4 ng of p24Aggag was
adsorbed to 0.5 ml of cell suspensions for 2 h. The cell-free
virus was thoroughly washed out, and cells were resus-
pended in 1 ml of growth medium supplemented with re-
combinant IL-2 and seeded in 24-well plates. Aliquots of
supernatants were collected twice a week and virus produc-
tion (p24Aggag) was assessed. Cultures were maintained for
2 weeks.
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